Intuitive Surgical's da Vinci 5 is gaining rapid adoption, fueling hospital upgrades as software enhancements build a potential multi-year capital cycle.
The Fund generated a net return of +15.24% during the second quarter, underperforming the Russell 1000 Growth Index return of +16.74%. Our weakest relative performance during the quarter came from the health care sector. Our strongest performance during the quarter came from the information technology sector.
Intuitive Surgical (ISRG) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
ISRG is expanding robotic surgery beyond urology as general surgery and newer specialties gain traction, creating fresh avenues for long-term procedure growth.
ISRG pairs durable platform demand and higher margin guidance with caution on softer U.S. procedure growth and deferred care.
Intuitive Surgical (NASDAQ:ISRG | ISRG Price Prediction) trades at $356.83, while the average Wall Street price target sits at $484.40.
The Silvant Large Cap Growth SMA returned +14.61% (gross)/+13.79% (net) for the quarter compared to the Russell 1000 Growth Index's return of +16.74%. ARM Holdings and Applied Materials were among the top stock contributors to relative performance. Netflix and Intuitive Surgical were among the largest stock detractors from relative performance.
The da Vinci 5 is driving growth throughout the business. This traditionally expensive stock has suddenly become a bargain.
Intuitive today announced a collaboration with Deion “Coach Prime” Sanders to help increase patient awareness and understanding of surgical options.
Eli Lilly has just begun tapping into the massive opportunity in chronic weight management. Intuitive Surgical can bounce back thanks to innovation, a strong moat, and a large addressable market.